Abstract 603P
Background
Glioblastoma is a malignant brain tumour with a high recurrence rate following stanadard first-line treatment. While there are currently guidelines from NICE and EANO on the postoperative surveillance intervals for these patients, they were not evidence-based, and the quality of such recommendations remains untested. We therefore set out to provide an evidence-based recommendation on the optimal postoperative radiological surveillance schedule for glioblastoma patients after surgical treatment, tailored based on the extent of surgical resection and completion of adjuvant treatment.
Methods
This was a territory-wide, multicentre retrospective analysis of consecutive adult patients with IDH-wildtype glioblastoma treated with surgery and radiotherapy (RT) across seven neurosurgical units in Hong Kong between 2006-2020 (n=228). Data were extracted from the Hong Kong Glioblastoma Registry (HK-GBM Registry). Interval-censored Kaplan-Meier curves were constructed for the stratified groups based on the event-free survival of included patients, defined as time from the start date of RT to the occurrence of any event (tumour progression or death). A piecewise exponential model with different hazard functions in predefined time intervals was used to describe each curve. Accordingly, adopting a 15% event rate criterion, we generated the surveillance schedules.
Results
For a 15% event yield each scan (15% event rate criterion), we propose that glioblastoma patients treated with gross total resection be monitored with MRIs around every 9 weeks until 86 weeks after starting RT. Meanwhile, patients with residual tumour after surgery should be monitored more frequently at every 7 weeks until 75 weeks after RT initiation; and the interval should be further shortened to every 4 weeks for patients who were unable to complete the standard 6-weeks concurrent chemoradiotherapy.
Conclusions
Radiological surveillance is an important tool to detect postoperative tumour progression. The extent of surgical resection and completion of adjuvant treatment are major factors associated with glioblastoma progression and the frequency of radiological surveillance should therefore be guided by these two factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Hong Kong Neuro-oncology Society.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract